Genmab (GMAB) updates Articles of Association in new Form 6-K filing

Rhea-AI Filing Summary

Genmab A/S filed a Form 6-K as a foreign private issuer for February 2026. The report primarily furnishes an updated corporate document, listing the company’s Articles of Association as Exhibit 3.1. The filing is also incorporated by reference into several existing Genmab Form S-8 registration statements.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF FEBRUARY 2026

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
3.1			Articles of Association

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: FEBRUARY 25, 2026

FAQ

What does Genmab (GMAB) report in this February 2026 Form 6-K?

Genmab’s February 2026 Form 6-K furnishes its updated Articles of Association as Exhibit 3.1. The filing is a corporate and legal update rather than a financial or earnings disclosure for investors.

Does Genmab’s February 2026 Form 6-K include financial results?

No, the February 2026 Form 6-K centers on corporate documentation, specifically the Articles of Association. It does not present earnings, revenue, or other financial performance data for Genmab A/S in this report.

How is this Genmab (GMAB) Form 6-K used in its S-8 registrations?

The Form 6-K is expressly incorporated by reference into multiple Genmab Form S-8 registration statements. This means the information in this report becomes part of those employee share and incentive plan registration documents.

What exhibit is attached to Genmab’s February 2026 Form 6-K?

The filing lists a single exhibit, labeled Exhibit 3.1, which is Genmab A/S’s Articles of Association. This document outlines key corporate governance terms and the company’s foundational organizational rules.

Who signed Genmab’s February 2026 Form 6-K filing?

The Form 6-K was signed on behalf of Genmab A/S by Anthony Pagano. He is identified in the filing as the company’s Executive Vice President and Chief Financial Officer, acting as an authorized signatory.

Filing Exhibits & Attachments

1 document

Other Documents

• EX-3.1 EX-3.1 230.2 KB